Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Motor Activity 22Breast Neoplasms 14Neoplasms 9Fatigue 5Prostatic Neoplasms 4Obesity 4Pancreatic Neoplasms 3Colorectal Neoplasms 3Peripheral Nervous System Diseases 2Overweight 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Cognitive Dysfunction 2Cardiovascular Diseases 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Smoking 1Skin Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Osteolysis 1Non-alcoholic Fatty Liver Disease 1Neuroectodermal Tumors, Primitive 1Neurocognitive Disorders 1Multiple Endocrine Neoplasia Type 1 1Metabolic Syndrome 1

Interventions

pembrolizumab 15Paclitaxel 15Carboplatin 13Specimen Handling 6Biopsy 6durvalumab 5Magnetic Resonance Spectroscopy 5dostarlimab 4Taxes 4Surveys and Questionnaires 4Observation 4Letrozole 4Everolimus 4Cisplatin 4olaparib 3lenvatinib 3ceralasertib 3Doxorubicin 3sacituzumab govitecan 2pertuzumab 2copanlisib 2cabozantinib 2atezolizumab 2abemaciclib 2Trastuzumab 2Robotic Surgical Procedures 2Pemetrexed 2Nivolumab 2Metformin 2Megestrol Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Neoplasms × Exercise × Clear all
NCT04000880 2025-06-12

AMPLIFY

University of Alabama at Birmingham

Phase NA Active not recruiting
603 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidPlasma cell

Breast Neoplasms, Kidney Neoplasms, Lymphoma, Non-Hodgkin, Motor Activity, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡